Prostaglandins and Expression of Lymphocyte Cytotoxicity

Part of the Prostaglandins, Leukotrienes, and Cancer book series (PLAC, volume 4)


The suggestion that prostaglandins may play an important role in immune response/tumor cell interactions is based upon several observations. First, a variety of prostaglandins are produced both by cells that are themselves active in the expression and regulation of immune response activity (1–4) as well as by a number of tumor targets (5,6). Second, the production of prostaglandins has been found to increase as a result of direct contact between effector lymphocytes and tumor targets (7). Third, prostaglandins at levels produced during these interactions have been shown to influence the ultimate expression in vitro of lymphocyte and macrophage cytotoxicity against tumor targets (8–12).


Tumor Target Cell Prostaglandin Production Splenic Lymphocyte Lymphocyte Cytotoxicity Cell Immunol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tomar RH, Darrow TL, John PA: Response to and production of prostaglandin by murine thymus, spleen, bone marrow, and lymph node cells. Cell Immunol (60): 335, 1981.PubMedCrossRefGoogle Scholar
  2. 2.
    Snider MW, Fertel RH, Zwilling BS: Prostaglandin regulation of macrophage function: effect of endogenous and exogenous prostaglandins. Cell Immunol (74): 234, 1982.PubMedCrossRefGoogle Scholar
  3. 3.
    Koga Y, Taniguchi K, Kubo C, Nomoto K: Peritoneal adherent cells inhibit the generation of cytotoxic T-lymphocytes with prostaglandin-mediated system. Cell ImmunoL (66): 195, 1982.PubMedCrossRefGoogle Scholar
  4. 4.
    Shimamura T, Hashimoto K, Sasaki S: Feedback suppression of the immune response in vivo. II. Involvement of prostaglandins in the generation of suppressor-inducer B lymphocytes. Cell Immunol (69): 192, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    Karnali RA: Review: prostaglandins and cancer. Prostaglandins Med (5): 11, 1980.CrossRefGoogle Scholar
  6. 6.
    Goodwin JS: Prostaglandin E and cancer growth potential for immunotherapy with prostaglandin synthetase inhibitors. IN: Hersh EM, Chirigos MA, Mastrangelo MJ (eds) Progress in Cancer Research and Therapy. Augmenting Agents in Cancer Therapy. Raven Press, New York, 1981, vol. 16, p 393.Google Scholar
  7. 7.
    Owen K, Gomolka D, Droller MJ: Lymphocyte-induced production of prostaglandin E2 by tumor cells in vitro: requirements for direct contact and lymphocyte viability. Cell Immunol (55): 428, 1980.PubMedCrossRefGoogle Scholar
  8. 8.
    McCarthy ME, Zwilling BS: Differential effects of prostaglandine on the anti-tumor activity of normal and BCG-activated macrophages. Cell Immunol (60): 91, 1981.PubMedCrossRefGoogle Scholar
  9. 9.
    Koren HS, Anderson SJ, Fischer DG, Copeland CS, Jensen PJ: Regulation of human natural killing. I. The role of monocytes, interferon, and prostaglandine. J Immunol (127): 2007, 1981.Google Scholar
  10. 10.
    Leung KH, Koren HS: Regulation of human natural killing. II. Protective effect of interferon on NK cells from suppression by PGE2. J Immunol (129): 1742, 1982.PubMedGoogle Scholar
  11. 11.
    Droller MJ, Lindgren JA, Claessen HE, Perlmann P: Production of prostaglandin E2 by bladder tumor cells in tissue culture and a possible mechanism of lymphocyte inhibition. Cell Immunol (47): 261, 1979.PubMedCrossRefGoogle Scholar
  12. 12.
    Brunda MJ, Herberman RB, Holden HT: Inhibition of murine killer cell activity by prostaglandins. J Immunol (124): 2682, 1980.PubMedGoogle Scholar
  13. 13.
    Kendall RA, Tarean S: The dual effect of prostaglandin and ethanol on the natural killer cytolytic process: effector activation and NK cell-target cell conjugate lytic inhibition. J Immunol (125): 2770, 1980.PubMedGoogle Scholar
  14. 14.
    Drysdale BE, Shin HS: Activation of macrophages for tumor cell cytotoxicity: identification of indomethacin sensitive and insensitive pathways. J Immunol (127): 760, 1981.PubMedGoogle Scholar
  15. 15.
    Plescia OJ, Smith AH, Grimwich K: Subversion of the immune system by tumor cells and the role of prostaglandins. Proc Nat Acad Sci (72): 1848, 1975.PubMedCrossRefGoogle Scholar
  16. 16.
    Heney CS, Bourne HR, Lichtenstein LM: The role of cyclic 3’5’ adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (108): 1526, 1972.Google Scholar
  17. 17.
    Strom TB, Deisseroth A, Morganroth J, Carpenter CB, Merrill JP: Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Nat Acad Sci (69): 2995, 1972.PubMedCrossRefGoogle Scholar
  18. 18.
    Goodwin JS: Prostaglandin and regulation of mitogenesis. Cell Immunol (52): 239, 1980.PubMedCrossRefGoogle Scholar
  19. 19.
    Gordon D, Bray MA, Morley J: Control of lymphokine secretion by prostaglandins. Nature (262): 401, 1976.PubMedCrossRefGoogle Scholar
  20. 20.
    Baker PE, Fahey JV, Munck A: Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol (61): 52, 1981.PubMedCrossRefGoogle Scholar
  21. 21.
    Droller MJ, Schneider MU, Perlmann P: A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell Immunol (39):165, m 1978.PubMedCrossRefGoogle Scholar
  22. 22.
    Droller MJ, Perlmann P, Schneider MU: Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. Cell Immunol (39): 154, 1978.PubMedCrossRefGoogle Scholar
  23. 23.
    Erturk E, Price JM, Morris JE, Cohen S, Leith BS, vonEsch AM, Crovetti AJ: The production of carcinoma of the urinary bladder in rats by feeding N-[4–1(5-nitro-2-furyl)-2-thiazolyll formamide. Cancer Res (27): 1998, 1967.Google Scholar
  24. 24.
    Owen K, Gomolka D, Droller MJ: Production of prostaglandin E2 by tumor cells in vitro. Cancer Res (40): 3167, 1980.PubMedGoogle Scholar
  25. 25.
    Droller MJ, Gomolka D: Enhancement of natural cytotoxicity in lymphocytes from animals with carcinogen-induced bladder cancer. J Urol (129): 625, 1983.PubMedGoogle Scholar
  26. 26.
    Droller MJ, Gomolka D: Interferon induction and prostaglandin synthetase inhibition in the in vitro and in vivo manipulation of immune response expression in an animal model of bladder cancer. Cell Immunol (72): 1, 1982.PubMedCrossRefGoogle Scholar
  27. 27.
    Droller MJ, Gomolka D: Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model. Invest Urol, in press, 1984.Google Scholar
  28. 28.
    Droller MJ, Gomolka D: Inhibition of tumor growth in association with modifiction of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid. Cancer Res (42): 5038, 1982.PubMedGoogle Scholar
  29. 29.
    Bennett A, Charlier EM, McDonald AM: Prostaglandins and breast cancer. Lancet (2): 624, 1977.PubMedCrossRefGoogle Scholar
  30. 30.
    Bennett A, Carroll MA, Stamford IF: Prostaglandins and human lung carcinoma. Brit J Cancer (46): 888, 1982.PubMedCrossRefGoogle Scholar
  31. 31.
    Khan O, Hensby CN, Williams G: Prostacyclin in prostatic cancer: a better marker than bone scan or serum acid phosphatase? Brit J Urol (54): 26, 1982.PubMedCrossRefGoogle Scholar
  32. 32.
    Caro JF, Besarab A, Flynn JT: Prostaglandin E and hypercalcemia in breast carcinoma: only a tumor marker? A need for perspective. Amer J Med (66): 337, 1979.Google Scholar
  33. 33.
    Tanner NS, Stamford IF, Bennett A: Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer. Brit J Cancer (43): 767, 1981.PubMedCrossRefGoogle Scholar
  34. 34.
    Goodwin JS: Prostaglandin regulation of mitogenesis. Cell Immunol (52): 239, 1980.PubMedCrossRefGoogle Scholar
  35. 35.
    Murray JL: Prostaglandin E2 modulation of human monocyte antibody-dependent cell-mediated cytotoxicity against human red blood cells. Cell Imnunol (71): 196, 1982.CrossRefGoogle Scholar
  36. 36.
    Fischer A, Durandy A, Griscelli C: Role of prostaglandin E2 in the induction of non-specific T lymphocyte suppressor activity. J Immunol (126): 1452, 1981.PubMedGoogle Scholar
  37. 37.
    Goodwin JS, Webb DR: Regulation of the immune response by prostaglandins. Clin Immunol Imunopathol (15): 106, 1980.CrossRefGoogle Scholar
  38. 38.
    Goodwin JS, Messner RP, Bankhurst AD: Prostaglandin-producing suppressor cells in Hodgkin’s Disease. New Engl J Med (297): 963, 1977.PubMedCrossRefGoogle Scholar
  39. 39.
    Cameron DJ, O’Brien P: Relationship of the suppression of macrophage medicated tumor cytotoxicity in conjunction with secretion of prostaglandin from the macrophage of breast cancer patients. Int J Immunopharmacol (4): 445, 1982.PubMedCrossRefGoogle Scholar
  40. 40.
    Panje WR, Maca R: Prostaglandin inhibitor sensitive suppressor cells: a product of survival in advanced head and neck cancer. International Symposium on Prostaglandins and Cancer, Washington, D.C., 1981.Google Scholar
  41. 41.
    Favolli C, Leport P, Jaffe BM, Santoro MG, Simmett T, Gobbo VD, Garaci E: The differential effects of PGE on the immune response in normal and immunosuppressed mice. Cell Immunol (72): 351, 1982.CrossRefGoogle Scholar
  42. 42.
    Stringfellow DA: Prostaglandin restoration of the interferon response by hypoactive animals. Science (201): 376, 1978.PubMedCrossRefGoogle Scholar
  43. 43.
    Taffet SM, Pace JL, Russell SW: Lymphokine maintains macrophage activation for tumor cell killing by interfering with the negative regulatory effect of prostaglandin E,. J Immunol (127): 121, 1981.PubMedGoogle Scholar
  44. 44.
    Tilden AB, Balch CM: A comparison of prostaglandin E2 effects on human suppressor cell function and on interleukin 2 function. J Immunol (129): 2469, 1982.PubMedGoogle Scholar
  45. 45.
    Wolf M, Droege W: Inhibition of cytotoxic responses by prostaglandin E2 in the presence of interleukin 2. Cell Immunol (72): 286, 1982.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

There are no affiliations available

Personalised recommendations